PHVS Stock — Pharvaris N.V.: Cash, EV, Pipeline

What they do

Our first molecule, deucrictibant (previously referred to as PHA-022121 or PHA121), is a novel, oral, small-molecule bradykinin B2 receptor antagonist under development for the prevention or treatment of attacks due to bradykinin-mediated angioedema (AE-BK), including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH).

Source: 20-F FY2025 via SEC EDGAR

Share price

$34.39

Market cap

$2,395.8M

Cash

$328.2M

Enterprise value

$2,067.6M

Balance sheet

Cash	$328.2M
Debt	$0.0M
Net cash	$328.2M
Enterprise value	$2,067.6M
Basic shares	65.2M shares
Fully diluted shares	76.2M shares
Fully diluted market cap	$2,620.7M
Cash per share	$5.03

Cash figures as of 2025-12-31. Database snapshot: 2026-11-07.

Share structure

Common

70.2M

Pre-funded warrants

0.0M

Options

4.5M

RSUs

1.5M

Warrants

0.0M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

—

FDSO

76.2M

Cap table as of 2026-06-30.

Price history

Loading PHVS daily closes…

Loading price history…

Next catalyst

deucrictibant XR · Est. Apr 1, 2027 · half midpoint · guided in 8 wks

Recently reported

Deucrictibant Phase 3 Positive · 2026-10-08

hereditary angioedema (hae)

Source release →

Deucrictibant Phase 3 Positive · 2026-09-08

CHAPTER-3 · hereditary angioedema (hae)

Source release →

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Apr 1, 2027 in 8 wks half midpoint	deucrictibant XR CHAPTER-3 pivotal Phase 3, marketing authorization applications · NCT06669754	Phase 3	Not disclosed	starting H1 2027
GUIDEDApr 23, 2027 in 6 mo	deucrictibant IR NDA for on-demand treatment of HAE attacks, PDUFA target action date · NCT06343779	Not disclosed	on-demand treatment of HAE attacks	April 23, 2027
Jul 13 - Aug 24 in 8 mo	deucrictibant	Phase 3	Hereditary Angioedema; Hereditary Angioedema Type I; Hereditary Angioedema Type II	—
Jul 13 - Aug 24 in 8 mo	Deucrictibant	Phase 3	Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)	—
Jan 12 - Feb 23 in 27 mo	Deucrictibant	Phase 3	Hereditary Angioedema (HAE)	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

Deucrictibant IR

Phase 3 · Active Modality: oral capsule

Target bradykinin B2 receptor

Indications

On-demand treatment of hereditary angioedema (HAE) attacks (Phase 3)

Status note Immediate-release capsule. Topline data from RAPIDe-1, RAPIDe-2, and RAPIDe-3 released; RAPIDe-2 open-label extension ongoing. No NDA submission or PDUFA timing stated in 20-F excerpts.

Deucrictibant XR

Phase 3 · Active Modality: oral tablet (extended-release)

Target bradykinin B2 receptor

Indications

Prophylactic treatment of HAE attacks (Phase 3)

Status note Extended-release tablet. CHAPTER-1 proof-of-concept and safety data released; pivotal Phase 3 CHAPTER-3 ongoing; CHAPTER-4 open-label extension ongoing. No topline timing stated in 20-F excerpts.

Per-asset detail extracted from the 20-F filed 2026-04-02. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Deucrictibant
Lead indication	Hereditary Angioedema (HAE)
Lead phase	Phase 3
Active trials	4
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05396105	Phase 3	Enrolling by invitation	Sponsor	PHVS	—	Hereditary Angioedema; Hereditary Angioedema Type I; Hereditary Angioedema Type II	—
NCT07266805	Phase 3	Recruiting	Sponsor	PHVS	—	Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH)	—
NCT06679881	Phase 3	Recruiting	Sponsor	PHVS	—	Hereditary Angioedema (HAE)	—
NCT06669754	Phase 3	Active, not recruiting	Sponsor	PHVS	—	Hereditary Angioedema (HAE)	starting H1 2027 Est. Apr 1, 2027 · half midpoint
NCT05834777	Phase 3	Recruiting	Collaborator	Vanderbilt University Medical Center	—	Intradialytic Hypotension	—

Sponsor-matched active trials from ClinicalTrials.gov (4 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 5 active trials for Pharvaris Netherlands B.V. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Deerfield Management	3,376,042	+250,000	1.22%	2026-08-14
Cormorant Asset Management	750,000	-250,000	1.33%	2026-08-14
Ikarian Capital	308,856	-178,000	1.75%	2026-08-14
EcoR1 Capital	235,000	+235,000	0.40%	2026-08-14
OrbiMed Advisors	205,400	no change	0.13%	2026-08-14
ADAR1 Capital Management	105,528	no change	0.17%	2026-08-14
Baker Bros. Advisors	0	-375,000	0.00%	2026-08-14
Logos Global Management	0	-65,000	0.00%	2026-08-14
Great Point Partners	0	-82,800	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

PHVS — Pharvaris N.V. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Recently reported

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

PHVS — Pharvaris N.V.